Anti-DENV1 serum was administered 24 hours prior to a sub-lethal infection (105 PFU) of DENV2 D2S10, and animals were treated 24 hours post-infection with 20 μg of genetically-modified MAbs lacking effector functions, where the N297Q variant MAbs are fully aglycosylated and the LALA variant MAbs remain glycosylated but incapable of binding either FcγR or C1q [42], [46]. This evidence concerns the gene FCGR2A and infection.